Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years

Tattersfield, A. E.; Town, G. I.; Johnell, O.; Picado, C.; Aubier, M.; Braillon, P.; Karlström, R.
April 2001
Thorax;Apr2001, Vol. 56 Issue 4, p272
Academic Journal
Background--Inhaled corticosteroids are clearly beneficial for patients with asthma of moderate severity, but the risks and benefits of using them in patients with milder asthma are less clear. We have compared the change in bone mineral density over 2 years in adults with mild asthma randomised to receive an inhaled corticosteroid or non-corticosteroid treatment. Methods--Subjects with mild asthma (mean forced expiratory volume in one second (FEV1) 86% predicted, mean age 35 years, taking β agonists only) were randomised to receive inhaled budesonide, inhaled beclomethasone dipropionate, or non-corticosteroid treatment for 2 years in a prospective randomised open study in 19 centres in France, New Zealand, Spain, and the UK. The corticosteroid dose was adjusted according to a written self- management plan. The main outcome measure-change in bone mineral density after 6, 12, and 24 months--Was measured "blind". Secondary outcomes included lung function, the relation between change in bone density and inhaled steroid dose and change in biochemical markers of bone metabolism. Results--Of 374 subjects randomised, 239 (64%) completed the study and were included in the analysis. The median daily doses of inhaled budesonide (n=87) and beclomethasone (n=74) were 389 μg and 499 μg respectively. Subjects treated with an inhaled corticosteroid had better asthma control than those in the reference group (n=78). Change in bone mineral density did not differ between the three groups over the 2 years, nor did it correlate with changes in markers of bone metabolism. The mean change in bone mineral density over 2 years in the budesonide, beclomethasone dipropionate, and reference groups was 0.1%, -0.4%, and 0.4% for the lumbar spine and -0.9%, -0.9%, and -0.4% for neck of the femur. Mean daily dose of inhaled steroid was related to reduction in bone mineral density at the lumbar spine but not at the femoral neck. Conclusion--In subjects with mild asthma an inhaled corticosteroid provided better asthma control than alternative non-corticosteroid treatment with no difference in change in bone mineral density over 2 years. The relation between dose of inhaled corticosteroid and change in bone density at the lumbar spine may be due to a direct effect of inhaled corticosteroids on bone. Since inhaled steroid dose is also related inversely to lung function, an effect of asthma severity on bone density was also possible.


Related Articles

  • Combination inhalers backed for asthma.  // GP: General Practitioner;4/4/2008, p3 

    The article reports on the effectiveness of combination inhalers for the treatment of patients with chronic asthma. A combination device is required for adults and children over 12 years of age who need both an inhaled corticosteroid (ICS) and a long-acting beta-2 agonist (LABA). A combination...

  • Fluticasone Propionate via Diskusâ„¢ Inhaler at Half the Microgram Dose of Budesonide via Turbuhalerâ„¢ Inhaler. Backman, R.; Baumgarten, C.; Sharma, R.K. // Clinical Drug Investigation;2001, Vol. 21 Issue 11, p735 

    Objective: To evaluate the efficacy and tolerability of two inhaled corticosteroid treatment regimens, fluticasone propionate (FP) delivered from a Diskusâ„¢ inhaler and budesonide delivered from a Turbuhalerâ„¢ inhaler, in adult patients with asthma. Design and Setting: This was an...

  • Using national inventories for estimating environmental impacts of products from industrial sectors: a case study of ethanol and gasoline. Sengupta, Debalina; Hawkins, Troy; Smith, Raymond // International Journal of Life Cycle Assessment;May2015, Vol. 20 Issue 5, p597 

    Purpose: In order to understand the environmental outcomes associated with the life cycle of a product, to compare these outcomes across products, or to design more sustainable supply chains, it is often desirable to estimate results for a reference supply chain representative of the conditions...

  • Inhaled Budesonide/Formoterol Combination. McGavin, J.K.; Goa, K.L.; Jarvis, B. // Drugs;Jan2001, Vol. 61 Issue 1, p71 

    ▴ Current evidence suggests that the addition of the long acting inhaled β-agonist formoterol to low or moderate doses of the inhaled corticosteroid budesonide is effective in improving lung function and reducing the incidence of asthma exacerbations. ▴ Concurrent use of...

  • Development and Evaluation of Inhalational Liposomal System of Budesonide for Better Management of Asthma. PARMAR, J. J.; SINGH, D. J.; HEGDE, DARSHANA D.; LOHADE, A. A.; SONI, P. S.; SAMAD, A.; MENON, MALA D. // Indian Journal of Pharmaceutical Sciences;Jul/Aug2010, Vol. 72 Issue 4, p442 

    No abstract available.

  • LABA dangers highlighted. Cameron, Amanda // New Zealand Doctor;8/9/2006, p6 

    The article discusses research being done on long-acting beta agonists (LABA) to treat asthma patients. It references a study by Shelley Salpeter et al, published in the 2006 issue of the "Annals of Internal Medicine." Clarification of the use of LABA in combination with inhaled corticosteroid...

  • The use of combined inhalers in asthma. Cates, Christopher // Practice Nursing;Oct2008, Vol. 19 Issue 10, p508 

    The article focuses on the use of inhaled therapy for asthma and how to adjust therapy to suit individual needs. It mentions different types of inhaled therapy including inhaled steroids, beta agonists, combination inhalers, and corticosteroids. A table which outlines the recommended step...

  • Increased risk of treatment failure for older asthma patients.  // British Journal of Hospital Medicine (17508460);2015, Vol. 76 Issue 7, p383 

    The article discusses research on the increased risk of treatment failure for patients aged 30 years and older, referencing a study by R. M. Dunn and colleagues published in the 2015 issue of the "American Journal of Respiratory and Critical Care Medicine."

  • Independent Nurse: Journals Watch - Inhaled corticosteroids worsen male asthma in the long term.  // GP: General Practitioner;2/10/2006, p72 

    This article reports that a new study has found that inhaled corticosteroids worsen male asthma in the long term. A study of 281 patients with moderate to severe asthma found that after 23 years follow-up, mean FEV1 declined by 20.6ml/year in men who had used inhaled corticosteroids, but not in...


Read the Article


Sign out of this library

Other Topics